Benjamin P. Levy, MD, talks about the role chemotherapy currently plays in an arena where the cancer care team is emphasizing genomic profiling and targeted therapies to treat patients with lung cancer.
The common driver genes in non–small-cell lung cancer (NSCLC) include EGFR, ALK, andKRAS. C-MET amplification coexisting with EGFR mutation is recognized as a mechanism of primary resistance to EGFR tyrosine kinase inhibitors (TKIs).1,2 Lou and coworkers investigated the frequency of [ Read More ]
Pembrolizumab (pembro) is a humanized anti-PD1 monoclonal antibody approved in the United States for treating PD-L1–expressing advanced non–small-cell lung cancer (NSCLC) that progressed after platinum-based chemotherapy and an approved EGFR or ALK inhibitor. In the phase 3 KEYNOTE-010 study, pembro [ Read More ]